Gain a deeper knowledge of endocrine resistance mechanisms and treatment selection for ER-positive/HER2-negative metastatic breast cancer after progression

https://www.medscape.org/advances/oral-serds-2025a1000o90?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_437674.35_ace_launch ER-Positive/HER2-Negative Metastatic Breast Cancer: Navigating Endocrine Resistance and Expanding Treatment Options Endocrine therapy remains the cornerstone of treatment for ER-positive/HER2-negative metastatic breast cancer, yet both intrinsic and acquired resistance ultimately limit its long-term success. Resistance arises through diverse mechanisms—including activating ESR1 mutations, crosstalk with growth factor signaling pathways, and epigenetic changes—that allow tumor cells to bypass estrogen receptor blockade. New oral selective estrogen receptor degraders (SERDs) are designed to directly target and degrade the estrogen receptor, offering the potential to overcome ESR1-mediated resistance while providing the convenience of once-daily dosing. A deep understanding of endocrine resistance mechanisms is essential to identify which patients will derive the greatest benefit, to inform rational combination strategies, and ultimately to extend disease control and improve quality of life in this challenging clinical setting. This educational resource designed with the oncology team in mind, including oncologists, obstetrician/gynecologists, pathologists, nurse practitioners, nurses, and pharmacists, offers CME activities that feature insights from leading experts, along with engaging slide kits, clinical articles, and links to valuable resources. Together, these materials create a dynamic community of learning focused on enhancing patient care and achieving positive outcomes.